Eli Lilly announced on December 1, 2025, that it is lowering the cash price for starting doses of its popular weight-loss drug, Zepbound, when purchased through its LillyDirect platform. The price for the lowest single-dose vial (2.5 mg) has been cut to $299 from $349, and the 5 mg dose is now $399, down from $499. This move follows similar price reductions by competitor Novo Nordisk for its drugs Wegovy and Ozempic and comes after both companies reached a deal with the Trump administration to make these highly sought-after obesity treatments more affordable for patients. The price adjustments are seen as a response to both competitive dynamics and increasing political scrutiny over the high cost of GLP-1 medications. Following the announcement, Eli Lilly's stock experienced a slight downturn, with shares falling nearly 1% in premarket trading and trading down 0.8% during the day. The market's reaction appears to reflect the potential impact of lower prices on revenue for one of the company's key growth drivers.